PNC Financial Services Group’s Aldeyra Therapeutics ALDX Stock Holding History

PNC Financial Services Group’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$624	Sell	369 -177	-32%	-$775	﹤0.01%	4864
2025 Q4	$2.83K	Sell	546 -467	-46%	-$2.4K	﹤0.01%	4438
2025 Q3	$5.29K	Buy	1,013 +472	+87%	+$2.46K	﹤0.01%	4181
2025 Q2	$2.07K	Buy	541 +447	+476%	+$1.16K	﹤0.01%	4397
2025 Q1	$541	Buy	94 +60	+176%	+$355	﹤0.01%	4627
2024 Q4	$170	Hold	34	–	–	﹤0.01%	4661
2024 Q3	$183	Hold	34	–	–	﹤0.01%	4686
2024 Q2	$113	Buy	+34	New	+$133	﹤0.01%	4712
2023 Q3	–	Sell	-246	Closed	-$2.06K	–	4608
2023 Q2	$2.06K	Hold	246	–	–	﹤0.01%	4373
2023 Q1	$2.44K	Hold	246	–	–	﹤0.01%	4258
2022 Q4	$1.71K	Hold	246	–	–	﹤0.01%	4298
2022 Q3	$1K	Buy	+246	New	+$1.48K	﹤0.01%	4279
2022 Q2	–	Sell	-40	Closed	–	–	4460
2022 Q1	$0	Buy	+40	New	+$159	﹤0.01%	4500
2021 Q4	–	Sell	-248	Closed	-$2K	–	4426
2021 Q3	$2K	Buy	248 +197	+386%	+$1.81K	﹤0.01%	4077
2021 Q2	$1K	Buy	+51	New	+$613	﹤0.01%	4083

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PNC Financial Services Group's ALDX Position: Q1 2026 in Review

PNC Financial Services Group reduced its Aldeyra Therapeutics (ALDX) stake by 32% in Q1 2026, selling an estimated $775 and leaving 369 shares worth $624. The position accounts for ﹤0.01% of the portfolio, ranked #4864.

PNC Financial Services Group first reported a position in ALDX in Q2 2021 and has held it in 15 quarters since. The position peaked at $5.29K in Q3 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

PNC Financial Services Group held 369 shares of Aldeyra Therapeutics worth $624 as of Q1 2026.
PNC Financial Services Group sold 177 Aldeyra Therapeutics shares in Q1 2026, an estimated $775.
Aldeyra Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #4864 holding.
PNC Financial Services Group first reported a position in Aldeyra Therapeutics in Q2 2021 and has held it in 15 quarters since.
PNC Financial Services Group's Aldeyra Therapeutics position peaked at $5.29K in Q3 2025.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.